Teleflex, whose shares sank nearly 20% Thursday, will acquire most of Biotronik’s vascular intervention assets. Teleflex also ...

Medical devices provider, Teleflex (NYSE:TFX) said on Thursday that it will acquire all of the vascular intervention business ...

Teleflex's business units, including urology and acute care will come under NewCo, with interventional and surgical under ...

Teleflex to separate into two companies by mid-2026 and acquire Biotronik's Vascular Intervention unit for €760 million. CFO ...

Teleflex has announced a plan to split its business into two separate independent companies—and it’s setting up one of its ...

Biotronik today announced a strategic shift that includes the divestiture of its Vascular Intervention (VI) business to ...

Piper Sandler analyst Matt O’Brien downgraded Teleflex (TFX) to Neutral from Overweight with a price target of $140, down from $255. The ...

After the split, Teleflex would focus on devices for bloodstream and heart procedures, along with medical imaging, while ...

Teleflex (NYSE: TFX) announced today that it plans to separate its Urology, Acute Care and OEM businesses into a new publicly ...

Teleflex shares tumbled to a 52-week low on Thursday after the medical-technology company posted disappointing financial guidance and unveiled plans for a nearly $800 million acquisition and a spinoff ...

Acquisition will further advance Teleflex’s Interventional portfolio with a differentiated global suite of coronary vascular ...

Teleflex (TFX) announced it has entered into a definitive agreement to acquire substantially all of the Vascular Intervention business of ...